X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Product Name: Trelstar
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 01, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Dexa Medica’s nation-wide launch and distribution of triptorelin, as Debiopharm’s exclusive Indonesian licensee, will help patients in the region gain access to the pain-relieving benefits of hormone suppression with Pamorelin®.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Pamorelin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2021
Details:
The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Product Name: Trelstar
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Verity Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2020
Details:
The agreement grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada.
Lead Product(s): Triptorelin Pamoate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Knight Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
